OS Therapies (OSTX) Operating Expenses (2023 - 2026)
OS Therapies' (OSTX) quarterly Operating Expenses came in at $2.8 million in Q1 2026, down 23.69% YoY from $3.7 million in Q1 2025, and up 164.4% on a QoQ basis from -$4.4 million in Q4 2025.
OS Therapies (OSTX) Operating Expenses (2023 - 2026) Analysis & Trends
OS Therapies (OSTX) has 4 years of Operating Expenses data on file, last reported at $2.8 million in Q1 2026.
- Quarterly Operating Expenses fell 23.69% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.2 million (up 42.69% YoY) and the FY2025 annual result came in at $12.3 million, up 203.95% from the prior year.
- Operating Expenses improved to $2.8 million in Q1 2026, from -$4.4 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $6.9 million in Q3 2025 to a low of -$4.4 million in Q4 2025.
- A 4-year average of $1.7 million and a median of $1.2 million in 2023 frame the typical range for Operating Expenses.
- The widest YoY moves for Operating Expenses: up 520.51% in 2025, down 2142.89% in 2025.
- Tracing OSTX's Operating Expenses over 4 years: stood at $1.2 million in 2023, then sank by 81.5% to $214051.0 in 2024, then tumbled by 2142.89% to -$4.4 million in 2025, then surged by 164.4% to $2.8 million in 2026.
- The last three Operating Expenses figures came in at $2.8 million (Q1 2026), -$4.4 million (Q4 2025), and $6.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | OS Therapies | 19.31 Mn | 19.31 Mn | - | 8.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.82 Mn |
| Dec 31, 2025 | -4.37 Mn |
| Sep 30, 2025 | 6.88 Mn |
| Jun 30, 2025 | 4.84 Mn |
| Mar 31, 2025 | 3.69 Mn |
| Dec 31, 2024 | 214,051.00 |
| Sep 30, 2024 | 2.44 Mn |
| Jun 30, 2024 | 779,800.00 |
| Mar 31, 2024 | 630,232.00 |
| Dec 31, 2023 | 1.16 Mn |
| Sep 30, 2023 | 622,208.00 |
| Jun 30, 2023 | 1.52 Mn |
| Mar 31, 2023 | 1.05 Mn |